All News

lupus.nephritis.immunofluorescence.jpg

Long Term Safety and Efficacy of Tacrolimus in Lupus Nephritis

Jack Cush, MD

Takeuchi et al has published their large experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Hydroxychloroquine Shortage During COVID-19

Jack Cush, MD

According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic.

Read Article
steroid prednisone lab

Corticosteroid Use Hikes CV Risks in Rheumatic Patients

Jack Cush, MD

UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.

Read Article
FINAL 2020 Podcast Graphic

RheumNow Podcast – Lights, Camera, Zoom (1.8.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.

Read Article
pill pillbox adherence

Adherence to Hydroxychloroquine Lowers Lupus Mortality

Jack Cush, MD

A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality. 

Read Article
cardiac2.jpg (keep)

Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis

Jack Cush, MD

Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often refractory to glucocorticoids and colchicine.

Read Article
pills.bottle.hand__0.jpg

EULAR Guidance on Patient Adherence to Meds

Jack Cush, MD

Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease.  It has been estimated that 30-80% of patients with rheumatic and musculoskeletal diseases (RMDs) are nonadherent to prescribed regimens.  EULAR has commissioned a task force

Read Article
backpain.hip_.jpg (keep)

Spinal Benefits Seen With Cosentyx in PsA

MedPage Today

Secukinumab (Cosentyx) was effective for axial manifestations of psoriatic arthritis in a 52-week multicenter phase III study, investigators reported.

Read Article
Corticosteroid Use Hikes CV Risks in Rheumatic Patients--It is long known that high-dose steroids may increase the risk of cardiovascular disease (CVD), heart disease, stroke, or other vascular outcomes, but it is unknown what the risk is at lower doses. https://t.co/gkTLP3ceVD https://t.co/HMpvpham1q

Links:

Dr. John Cush RheumNow ( View Tweet)
SOBI announced Kineret is now FDA approved to treat DIRA (defic of IL-1 receptor antagonist), an ultra-rare, autoinflammatory Dz caused by a genetic mutation in the IL1RN gene,. Pts have life-threatening systemic inflammation with skin and bone involvement https://t.co/iccvWYJva9

Links:

Dr. John Cush RheumNow ( View Tweet)

A oatint infected with COVID-19- Yes they should get vaccinated ~90days after infection has resolved.Antibody testing is not needed before you are vaccinated. Evidence suggests that reinfection is uncommon in the 90 days after initial infection. https://t.co/TkcSNx0hF1.

Links:

Dr. John Cush RheumNow ( View Tweet)

Preprint results of the REMAP-CAP trial in the UK shows that IL-6 inhibitors, when given within 24 hrs of ICU entry for COVID-19, lowers mortality rate by 36%. Hosp mortality in 353 TCZ was 28%, 48 sarilumab was 22% in 402 controls was 36%. https://t.co/fkjOz99t0l

Links:

Dr. John Cush RheumNow ( View Tweet)

ACR Convergence 2020 Late Breaking Abstracts available from the ACR "Spotlight" slide give away. 10 slides on COVID, Tyk2 in PsA, FAST febuxostat study, Tofa in AS and novel drugs for SLE and PSS https://t.co/DvcDyusCUR

Links:

Dr. John Cush RheumNow ( View Tweet)

Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis RHAPSODY was a phase 3 multicenter, double-blind, event-driven, randomized-withdrawal trial of rilonacept in 86 patients with recurrent pericarditis Read more: https://t.co/syibq4X7Ps https://t.co/gnxlpOGiHA

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR Guidance on Patient Adherence to Meds--Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease. https://t.co/XwxkFz66fv https://t.co/E6W3H56jps

Links:

Dr. John Cush RheumNow ( View Tweet)
Petri et al shows higher HCQ levels associated with reduced thrombosis risk, study of 739 SLE pts - 38 patients (5.1%) had thrombosis. HCQ level lower in thrombosis pts (720 vs 935, p=0.025). 69% decr in VTE when levels >1068 ng/mL vs <648 ng/mL https://t.co/kis5zry7uH

Links:

Dr. John Cush RheumNow ( View Tweet)

Join us this March for RheumNow Live! Sign up via the link below. https://t.co/vJlU0Z3Q3x https://t.co/G1s3F7zKlI

Links:

Dr. John Cush RheumNow ( View Tweet)
Rifampin is safest! 2 RCTs of 6485 latent TB pts compared 9 mos of isoniazid vs 4 mos of rifampicin. RIF had half the adverse events compared to INH; roughly half the rate of rash (1.5% v 2.7%); No grade 3-4 hepatotoxicity w/ RIF, compared 6%) w/ INH https://t.co/6Nz0zeP8ik

Links:

Dr. John Cush RheumNow ( View Tweet)

Analysis of worldwide data on Abatacept shows that compared with other bDMARDs, ABA was not associated with an increased overall cancer risk [ROR 0.98 (95% CI 0.91, 1.05)], but may be increased for risk of melanoma [1.58 (95% CI 1.17, 2.08)] https://t.co/8IQRHoPqBl https://t.co/5MkvEKcNJg

Links:

Dr. John Cush RheumNow ( View Tweet)
MIRROR OL study shows that when pegloticase is co-administered with methotrexate, a high rate of response is seen (79% or 11/14 pts), achieved a complete response (sUA &lt; 6 mg/dL) at Month 6. Topline results announced by Horizon. https://t.co/DNIt5zs8xA

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×